Frontier Investment Management’s GSK GSK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-5,612
Closed -$266K 283
2020
Q1
$266K Sell
5,612
-4,525
-45% -$241K 0.02% 207
2019
Q4
$595K Buy
10,137
+257
+3% +$14.3K 0.03% 160
2019
Q3
$527K Buy
9,880
+3,557
+56% +$183K 0.03% 149
2019
Q2
$316K Buy
6,323
+1,363
+27% +$68.4K 0.02% 193
2019
Q1
$259K Sell
4,960
-400
-7% -$20K 0.02% 220
2018
Q4
$256K Buy
5,360
+480
+10% +$23.6K 0.02% 208
2018
Q3
$245K Sell
4,880
-80
-2% -$4.07K 0.02% 220
2018
Q2
$250K Buy
4,960
+80
+2% +$4.03K 0.02% 206
2018
Q1
$238K Sell
4,880
-160
-3% -$7.45K 0.02% 191
2017
Q4
$223K Sell
5,040
-240
-5% -$11.1K 0.02% 207
2017
Q3
$268K Hold
5,280
0.02% 188
2017
Q2
$285K Sell
5,280
-222
-4% -$11.8K 0.03% 187
2017
Q1
$284K Buy
5,502
+222
+4% +$11.3K 0.03% 160
2016
Q4
$254K Sell
5,280
-112
-2% -$5.53K 0.02% 170
2016
Q3
$2.91M Sell
5,392
-533
-9% -$29.2K 0.03% 158
2016
Q2
$321K Sell
5,925
-361
-6% -$19K 0.04% 153
2016
Q1
$319K Buy
6,286
+1,056
+20% +$52.6K 0.04% 137
2015
Q4
$264K Buy
5,230
+496
+10% +$25.3K 0.04% 134
2015
Q3
$228K Buy
+4,734
New +$246K 0.04% 149

Other funds holding GSK

Frontier Investment Management's GSK Position: Q2 2020 in Review

Frontier Investment Management sold out of GSK (GSK) in Q2 2020, closing a stake of 5,612 shares — an estimated $266K sold.

Frontier Investment Management first reported a position in GSK in Q3 2015 and held it in 19 quarters. The position peaked at $2.91M in Q3 2016. 840 funds tracked by Wall St. Rank hold GSK as of Q2 2020.

  • Frontier Investment Management reported no remaining GSK position as of Q2 2020 after selling out during the quarter.
  • Frontier Investment Management sold 5,612 GSK shares in Q2 2020, an estimated $266K.
  • Frontier Investment Management first reported a position in GSK in Q3 2015 and held it in 19 quarters.
  • Frontier Investment Management's GSK position peaked at $2.91M in Q3 2016.
  • 840 funds tracked by Wall St. Rank held GSK as of Q2 2020.

Based on Frontier Investment Management's 13F filing for Q2 2020, filed 11 Aug 2020.